Brief: Valbiotis To Launch Phase II/III REVERSE-IT Clinical Study On TOTUM-63

Valbiotis SA

08/07/2020 06:48

July 8 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * VALBIOTIS: AUTHORIZATION TO LAUNCH THE INTERNATIONAL PHASE
II/III REVERSE-IT CLINICAL STUDY ON TOTUM-63, TO REDUCE TYPE 2
DIABETES RISK FACTORS
    * THIS PHASE II/III STUDY, HAS BEEN DESIGNED JOINTLY WITH
NESTLÉ
HEALTH SCIENCE'S TEAMS AS PART OF GLOBAL STRATEGIC PARTNERSHIP
    * FAVOURABLE OPINION FROM FRENCH ETHICAL COMMITTEE (CPP) AND
AUTHORIZATION FROM FRENCH NATIONAL AGENCY FOR SAFETY OF
MEDICINES AND HEALTH PRODUCTS (ANSM)
    * INTERNATIONAL STUDY WILL INCLUDE 600 SUBJECTS WITH ALTERED
GLUCOSE METABOLISM, SPANNING FROM ELEVATED FASTING GLYCEMIA TO
EARLY, YET UNTREATED, TYPE 2 DIABETES. ITS PRIMARY ENDPOINT IS
FASTING GLYCEMIA

Source text for Eikon:  ID:nBw693Ytha 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))